Pfizer, Inc. · NYSE:PFE
Pfizer — Investor Day (September 2020)
30 slides from Pfizer's investor day presentation, Sep 15, 2020
Slide 1: COVID-19 R&D
COVID-19 R&D 1
Slide 2: Forward-Looking Statements and Other Notices
Forward-Looking Statements and Other Notices Our discussions during Pfizer’s Investor Day include forward-looking statements about our anticipated future operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates,
Slide 3: Mikael Dolsten, MD, PhD
Mikael Dolsten, MD, PhD Chief Scientific Officer and President, Worldwide Research Development and Medical (WRDM) 3
Slide 4: Pfizer's Multi-Faceted Response to the COVID-19 Pandemic
Pfizer’s Multi-Faceted Response to the COVID-19 Pandemic Vaccine Potentially help prevent disease using mRNA technology Antiviral Advancing our potential first-in-class protease inhibitor as an investigational therapeutic Exploratory Studying existing pipeline assets 4
Slide 5: Pfizer's Multi-Faceted Response to the COVID-19 Pandemic
Pfizer’s Multi-Faceted Response to the COVID-19 Pandemic Vaccine Potentially help prevent disease using mRNA technology Antiviral Advancing our potential first-in-class protease inhibitor as an investigational therapeutic Exploratory Studying existing pipeline assets 5
Slide 6: First in Class SARS-CoV-2 Protease Inhibitor May Provide Novel Treatment Option for COVID-19
First in Class SARS-CoV-2 Protease Inhibitor May Provide Novel Treatment Option for COVID-19 PF-00835231 has potent in vitro single-agent antiviral activity against circulating SARS-COV-2 PF-00835231 has broad in vitro activity strains against coronavirus threats2 Coronavirus Ki (nM) Beta/gamma-CoV
Slide 7: First in Class SARS-CoV-2 Protease Inhibitor has Additive Activity with Remdesivir In Vitro
First in Class SARS-CoV-2 Protease Inhibitor has Additive Activity with Remdesivir In Vitro Due to Differentiated Mechanism of Action* EC90 PF-00835231 Remdesivir (nM) (nM) 190 <0.78 95 54.5 48 123 0 433 *HELA-ACE2 cell assay EC90 = The concentration required for a 90% response Boras et al. 2020. ht
Slide 8: Pfizer Expects Early Clinical Data for this Investigational Intravenous Anti-Viral
Pfizer Expects Early Clinical Data for this Investigational Intravenous Anti- Viral for Hospitalized COVID-19 Patients in Q4 2020 • PF-07304814 is a solubilizing IV pro-drug, designed to deliver the anti-viral active drug PF-00835231 clinically • Predicted to safely deliver plasma concentrations of
Slide 9: Pfizer's Multi-Faceted Response to the COVID-19 Pandemic
Pfizer’s Multi-Faceted Response to the COVID-19 Pandemic Vaccine Potentially help prevent disease using mRNA technology Antiviral Advancing our potential first-in-class protease inhibitor as an investigational therapeutic Exploratory Studying existing pipeline assets 9
Slide 10: The Potential of BioNTech's mRNA Vaccine Platform
The Potential of BioNTech’s mRNA Vaccine Platform* Safety Efficacy Speed Non-infectious and chemically Broad immune Technology enables defined, contains no viral responses based on rapid development and foreign proteins; early data, minimal quick production spike antigen encoded in mRNA risk of anti
Slide 11: Overview of COVID-19 Lipid Nanoparticle Design
Overview of COVID-19 Lipid Nanoparticle Design Encapsulated mRNA Lipids • Modified mRNA base structure • Chemically defined lipid particle • Codon optimized sequence • No ability to infect and spread • Encodes the viral spike protein • No foreign viral proteins included • Broad anti-viral spike immu
Slide 12: Growth Opportunity with mRNA Platform Across Three Waves
Growth Opportunity with mRNA Platform Across Three Waves WAVE 1 WAVE 2 WAVE 3 SARS-CoV-2 Next Gen Expanding the Pandemic SARS-CoV-2 Platform • Cutting-edge design of lipid • Opportunity for next gen SARS-CoV- • Opportunity to expand the nanoparticle and modified mRNA 2 mRNA vaccine in 2021 with a pl
Slide 13: Kathrin Jansen, PhD
Kathrin Jansen, PhD Senior Vice President & Head of Vaccine R&D 13
Slide 14: Pfizer and BioNTech COVID-19 mRNA Vaccine Program Overview
Pfizer and BioNTech COVID-19 mRNA Vaccine Program Overview Four Vaccine Candidates Spike Protein RNA Variant Target Immunization construct 162a1 RBD subunit uRNA prime / boost 162b1 RBD subunit modRNA prime / boost P2-mutated full SARS-COV-2 162b2 modRNA prime / boost spike protein (3D Model) P2-mut
Slide 15: Why We Chose BNT162b2 Variant for Pivotal Study
Why We Chose BNT162b2 Variant for Pivotal Study BioNTech mRNA vaccines are designed to induce a broad immune response including immunostimulatory dendritic cell delivery and expression1,2 Challenge Data Tolerability Antibody Responses Cellular Responses No or only transient Local reactions and Stron
Slide 16: BNT162b2 Immunization Prevents Lung Infection in Rhesus Macaques
BNT162b2 Immunization Prevents Lung Infection in Rhesus Macaques After Challenge with SARS-CoV-2 Bronchoalveolar Lavage (Lung) Bronchoalveolar Lavage (rhesus macaques) 10 10 2/3 Sentinel Control Viral RNA (copies) BNT162b2 10 8 10 6 1/3 10 4 0/3 0/3 0/6 0/3 0/6 0/3 0/6 0/6 Lower Limit of Detection n
Slide 17: After Dose of 30μg BNT162b2, Mostly Mild to Moderate Tolerability (US Phase 1)
After Dose 1 of 30μg BNT162b2, a Mostly Mild to Moderate Tolerability Profile is Observed (US Phase 1 Data) 100% N= 12 for 30µg; N=9 for Placebo Mild Moderate Severe Grade 4 18-55 year olds 80% 60% 50% 42% 40% 33% 33% 33% 25% 17% 17% 20% 8% 0% 0% 0% 0% 0% 0% 30µg Placebo 30µg Placebo 30µg Placebo 30
Slide 18: After Dose of 30μg BNT162b2, Mostly Mild to Moderate Tolerability (US Phase 1)
After Dose 2 of 30μg BNT162b2, a Mostly Mild to Moderate Tolerability Profile is Observed (US Phase 1 Data) 100% N= 12 for 30µg; N=9 for Placebo Mild Moderate Severe Grade 4 18-55 year olds 80% 75% 67% 56% 58% 58% 60% 40% 17% 17% 20% 11% 11% 0% 0% 0% 0% 0% 0% 30µg Placebo 30µg Placebo 30µg Placebo 3
Slide 19: BNT162b2 30μg Demonstrated Strong Neutralizing Antibody Responses
BNT162b2 30μg Vaccine Candidate Demonstrated Strong SARS-CoV-2 Neutralizing Antibody Responses in Younger and Older Adults (US Phase 1 data) At Day 35, 30µg BNT162b2 elicited SARS-CoV-2 neutralizing GMTs in 18-55 and 65-85 year olds well above the GMT of a HCS panel N=12 N=12 N=11 N=10 N=12 N=12 N=1
Slide 20: BNT162b2 Elicits Strong CD4+ and CD8+ T Cell Responses in German Trial
BNT162b2 Elicits Strong CD4+ and CD8+ T Cell Responses in Phase 1/2 German Trial CD4+ T cells CD8+ T cells Pre Post Pre Post RBD S Pool 1 S Pool 2 CEF CEFT Control 10 µg BNT162b2 Receptor binding domain (RBD) N-terminal portion of the spike protein (S Pool 1) C-terminal domain of the spike protein (
Slide 21: Phase 3 Efficacy Trial: 29,012 Participants Enrolled Across 129 Sites
Phase 3 Efficacy Trial: 29,012 Participants are Currently Enrolled Across 129 Sites in 3 Countries Primary Efficacy Objectives Primary Efficacy Objectives Endpoints Endpoints Clinical Sites Across The Globe COVID-19 incidence based on Planned Efficacy against confirmed COVID-19 in confirmed NAAT in
Slide 22: Rigorous Safety Monitoring Through All Phases of the Study
Rigorous Safety Monitoring Through All Phases of the Study • Safety and tolerability are being continuously scrutinized throughout the course of our study • Continuous monitoring is performed by Pfizer’s qualified personnel by reviewing individual and aggregate data on a blinded basis • Weekly revie
Slide 23: Blinded US Phase 3 Data Through August 27th: Tolerability Profile
Blinded US Phase 3 Data Through August 27th: After Dose 1 of 30μg BNT162b2 or Placebo, a Mostly Mild to Moderate Tolerability Profile is Observed 100% Mild Moderate Severe Grade 4 18-64 year olds 80% N= 5,664 60% 38% 40% 35% 20% 15% 9% 11% 8% 2% 0% Fever Fatigue Headache Chills Diarrhea Muscle pain
Slide 24: Blinded US Phase 3 Data Through August 27th: Tolerability Profile
Blinded US Phase 3 Data Through August 27th: After Dose 2 of 30μg BNT162b2 or Placebo, a Mostly Mild to Moderate Tolerability Profile is Observed 100% Mild Moderate Severe Grade 4 18-64 year olds 80% N= 1,237 60% 40% 36% 28% 16% 18% 20% 10% 7% 9% 0% Fever Fatigue Headache Chills Diarrhea Muscle pain
Slide 25: Angela Hwang
Angela Hwang Group President, Pfizer Biopharmaceuticals 25
Slide 26: The Pfizer-BioNTech Collaboration Has Created a Strong and Uniquely Positioned Development Program
The Pfizer-BioNTech Collaboration Has Created a Strong and Uniquely Positioned Development Program 130+ years of Development and Commercialization All In House End-to-End Vaccine Capabilities Among Vaccines suppliers with targeted launch in 2020, Pfizer-BioNTech is the ONLY collaboration that unique
Slide 27: Pandemic Phase Expected to Deliver Up To 100 Million Doses in 2020
Pandemic Phase Expected to Deliver Up To 100 Million Doses in 2020 and Approximately 1.3 Billion Doses in 2021 of Our Potential COVID-19 Vaccine Subject to regulatory approval >450M Doses Committed to Date for 2020-2021 Increasing Vaccine Confidence Options for Up To 600M Additional Doses EU: Delive
Slide 28: Distribution Plan Includes Options for Points of Use to Store COVID Vaccine
Distribution Plan Includes Options for Points of Use (POUs) to Store COVID Vaccine Up To 6 Months Direct Shipment to Point of Vaccine Storage Vaccine Preparation Vaccination Each thermal shipper arrives Ultra-Low From storage 1 vial used for with a reusable GPS Temperature Freezer every 5 patients t
Slide 29: mRNA Technology is Well-Positioned to Cover a Range of Potential COVID-19 Vaccination Scenarios
mRNA Technology is Well-Positioned to Cover a Range of Potential COVID-19 Vaccination Scenarios* *Subject to regulatory approval mRNA Technology Has Vaccine Durability Will Inform Vaccination Frequency Potential for Benefits in Any Vaccination Scenario Immunity Scenarios mRNA Technology May Allow Fa
Slide 30: Q&A
Q&A 30